BioXcel Therapeutics (BTAI) announced the enrollment of the first patients in a U.S. Department of War-funded Phase 2a clinical trial evaluating BXCL501 for the treatment of acute stress reactions, also known as acute stress disorder. The trial is being led by the University of North Carolina at Chapel Hill Institute of Trauma Recovery and marks a significant milestone in the collaboration between BioXcel Therapeutics and UNC.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- BioXcel Therapeutics: Undervalued Franchise with IGALMI PDUFA Catalyst Supports Buy Rating Despite Reduced Target
- BioXcel Therapeutics price target lowered to $5 from $6 at H.C. Wainwright
- FDA Accepts BioXcel sNDA for At-Home IGALMI Use
- BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA
- Morning Movers: AstraZeneca jumps following tozorakimab trial results